Clinical Trials
21
Active:2
Completed:13
Trial Phases
4 Phases
Phase 1:6
Phase 3:7
Phase 4:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Phase 3
7 (36.8%)Phase 1
6 (31.6%)Phase 4
3 (15.8%)Not Applicable
2 (10.5%)phase_1_2
1 (5.3%)A Study to Evaluate the Safety of Tetravalent Rotavirus Vaccine in Healthy Indian Adult Male Volunteers
Phase 1
Completed
- Conditions
- Rotavirus Gastroenteritis
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Shantha Biotechnics Limited
- Target Recruit Count
- 20
- Registration Number
- NCT01091298
- Locations
- 🇮🇳
Christian Medical College, Vellore, TamilNadu, India
Safety and Immunogenicity Study of the Tetravalent Rotavirus Vaccine
Phase 1
- Conditions
- Rotavirus Gastroenteritis
- First Posted Date
- 2010-02-03
- Last Posted Date
- 2010-10-04
- Lead Sponsor
- Shantha Biotechnics Limited
- Target Recruit Count
- 90
- Registration Number
- NCT01061658
- Locations
- 🇮🇳
Christian Medical College, Vellore, Tamilnadu, India
Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine
Phase 4
- Conditions
- DiphtheriaTetanusPertussisHepatitis BHaemophilus Influenzae Type B
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2009-05-06
- Lead Sponsor
- Shantha Biotechnics Limited
- Target Recruit Count
- 3000
- Registration Number
- NCT00877357
- Locations
- 🇮🇳
School of Public Health, Post Graduate Institute of Medical Education and Research, Chandigarh, UT, India
Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)
Phase 3
Completed
- Conditions
- Chemotherapy-Induced Neutropenia
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- Shantha Biotechnics Limited
- Target Recruit Count
- 126
- Registration Number
- NCT00776165
- Locations
- 🇮🇳
Indo American Cancer Institute and Research Centre, Hyderabad, Andhra Pradesh, India
🇮🇳Nizam's Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India
🇮🇳Vedanta Institute of Medical Sciences, Ahmedabad, Gujrat, India
Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian Infants
Phase 1
Withdrawn
- Conditions
- Rotavirus Infections
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2010-02-03
- Lead Sponsor
- Shantha Biotechnics Limited
- Target Recruit Count
- 240
- Registration Number
- NCT00757926
- Locations
- 🇮🇳
Christian Medical College, Vellore, Tamil Nadu, India
- Prev
- 1
- 2
- Next
News
No news found